{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000073","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.250068+00:00","generated_at":"2026-06-16T13:12:03.934855+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis to present positive Phase 1b data for azenosertib in ovarian cancer at ASCO; announces diagnostic partnerships","bullets":["Positive clinical data from Phase 1b trial of azenosertib + chemo in platinum-resistant ovarian cancer to be presented at ASCO June 5, 2023.","Cyclin E1 expression shown as predictive marker for clinical benefit from azenosertib.","Collaborations with Foundation Medicine and Roche Diagnostics to develop companion diagnostics for azenosertib.","Azenosertib is potentially first-in-class Wee1 inhibitor being investigated in multiple trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000073","json":"https://secwatch.observer/filing/0001725160-23-000073.json","markdown":"https://secwatch.observer/filing/0001725160-23-000073.md","text":"https://secwatch.observer/filing/0001725160-23-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000073/0001725160-23-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000073/zntl-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T13:12:03.934855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}